Phreesia (NYSE:PHR) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Phreesia (NYSE:PHR - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06, RTT News reports. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. During the same quarter last year, the firm posted ($0.05) earnings per share. Phreesia's revenue was up 14.5% compared to the same quarter last year. Phreesia updated its FY 2026 guidance to EPS.

Phreesia Stock Performance

Shares of Phreesia stock traded up $0.12 during trading on Friday, reaching $24.55. The company's stock had a trading volume of 672,417 shares, compared to its average volume of 440,425. Phreesia has a one year low of $17.07 and a one year high of $30.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -16.70 and a beta of 0.74. The business's fifty day moving average price is $24.80 and its 200-day moving average price is $25.28.

Insider Buying and Selling at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,213 shares of the firm's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total value of $28,881.53. Following the sale, the general counsel now directly owns 137,921 shares in the company, valued at $3,283,899.01. This trade represents a 0.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP David Linetsky sold 4,499 shares of Phreesia stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $23.73, for a total value of $106,761.27. Following the sale, the senior vice president now directly owns 217,239 shares in the company, valued at approximately $5,155,081.47. This trade represents a 2.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,474 shares of company stock valued at $1,023,208 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Caxton Associates LLP acquired a new stake in Phreesia during the first quarter valued at approximately $316,000. NewEdge Advisors LLC lifted its position in shares of Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company's stock worth $395,000 after buying an additional 11,181 shares during the period. Royal Bank of Canada boosted its stake in Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company's stock valued at $617,000 after buying an additional 16,309 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Phreesia by 3.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company's stock valued at $1,599,000 after acquiring an additional 2,158 shares during the period. Finally, AQR Capital Management LLC grew its position in Phreesia by 471.2% in the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company's stock valued at $4,090,000 after acquiring an additional 132,015 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on PHR. Canaccord Genuity Group lowered their target price on Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research note on Thursday. Truist Financial raised their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday. Citigroup reaffirmed a "buy" rating on shares of Phreesia in a research report on Wednesday. DA Davidson decreased their target price on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Finally, KeyCorp cut their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $31.64.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.